teprotumumab

Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). It is approved for the treatment of thyroid eye disease (TED), also known as Graves' eye disease, an autoimmune disorder characterized by inflammation and tissue remodeling behind the eyes. By binding to IGF-1R, teprotumumab blocks its activation and signaling, which reduces inflammation, prevents muscle and fat tissue remodeling, and decreases tissue expansion in the orbit. This mechanism helps alleviate symptoms such as proptosis (eye bulging), double vision, pain, redness, and swelling associated with TED. Teprotumumab was originally developed for oncology indications but was later repurposed for ophthalmic use. It is administered via intravenous infusion[2][3][5][6][7].

Brand names

Tepezza

Other names

teprotumumab-trbw